All In Biotech

NDA 205388 · Rayner Surgical

Omidria

Ketorolac Tromethamine, Phenylephrine Hydrochloride · Irrigation · alpha-1 Adrenergic Agonist; Nonsteroidal Anti-inflammatory Drug; Cyclooxygenase Inhibitor

Last checked: Nov 19, 2026Latest source record: Dec 8, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2014

May 30, 2014

Approved uses

2

Original approval plus efficacy supplements

Registered trials

238

46 Phase 3, 16 recruiting

FAERS reports

82

47 serious, 1 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Apr 8, 2026.

Omidria ® is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement and is indicated for maintaining pupil size by preventing intraoperative miosis and reducing postoperative ocular pain. OMIDRIA is an alpha 1-adrenergic receptor agonist and nonselective cyclooxygenase inhibitor indicated for: Maintaining pupil size by preventing intraoperative miosis ( 1 ) Reducing postoperative pain ( 1 ) OMIDRIA is added to an ocular irrigating solution used during cataract surgery or intraocular lens replacement.

Mechanism: The two active pharmaceutical ingredients (API) in Omidria, phenylephrine and ketorolac, act to maintain pupil size by preventing intraoperative miosis, and reducing postoperative pain. Phenylephrine is an α 1 -adrenergic receptor agonist and, in the eye, acts as a mydriatic agent by contracting the radial muscle of the iris. Ketorolac is a nonsteroidal anti-inflammatory that inhibits both cyclooxygenase enzymes (COX-1 and COX-2), resulting in a decrease in tissue concentrations of prostaglandins to reduce pain due to surgical trauma. Ketorolac, by inhibiting prostaglandin synthesis secondary...

Therapeutic areas: Pain and anesthesia

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • OMIDRIA · KETOROLAC TROMETHAMINE EQ 0.3% BASE; PHENYLEPHRINE HYDROCHLORIDE EQ 1% BASE · SOLUTION, IRRIGATION · Prescription · TE AT

Clinical trials

Interventional ClinicalTrials.gov studies with "Ketorolac Tromethamine" as an intervention, any sponsor and status, largest first.

All 238 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • endophthalmitis19
  • toxic anterior segment syndrome17
  • corneal oedema15
  • anterior chamber inflammation5
  • corneal opacity4
  • fibrin4
  • hypopyon4
  • iritis4
  • keratitis4
  • uveitis4
  • vitritis4
  • anterior chamber disorder3

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20151
201618
201716
20186
20196
20208
20216
20223
20239
20241
20258

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 280 on PubMed

Sponsor: Rayner Surgical

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.